- Conditions
- Rhinitis, Seasonal, Allergic
- Interventions
- PSE 120 mg, CM 8 mg, Atr 0.36 mg, PSE 120 mg, CM 8 mg, Atr 0.24 mg, PSE 120 mg, CM 8 mg, Atr 0.12 mg, PSE 120 mg, CM 8 mg, Atropine 0.24 mg
- Drug
- Lead sponsor
- Magna Pharmaceuticals, Inc.
- Industry
- Eligibility
- 12 Years to 60 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 4
- States / cities
- Stockbridge, Georgia • Louisville, Kentucky • Charleston, South Carolina + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Clinical Pharmacology
- Interventions
- Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-SAG), Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-Heist)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Secaucus, New Jersey
- Conditions
- Nasal Congestion
- Interventions
- Diphenhydramine 50 mg, Diphenhydramine 25 mg, Pseudoephedrine 120 mg
- Drug
- Lead sponsor
- Johnson & Johnson Consumer and Personal Products Worldwide
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 1,021 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 12
- States / cities
- Austin, Texas • Dallas, Texas • Kerrville, Texas + 4 more
- Conditions
- Urethral Sphincter Activity
- Interventions
- Pseudoephedrine, Tamsulosin, Imipramine, Cyclobenzaprine, Lactose capsule, Solifenacin
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years to 51 Years · Female only
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Acute Upper Respiratory Track Infection
- Interventions
- Guaifenesin, Placebo
- Drug · Device
- Lead sponsor
- Reckitt Benckiser Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,179 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 24
- States / cities
- Mesa, Arizona • Carmichael, California • Fresno, California + 21 more
- Conditions
- Clinical Pharmacology
- Interventions
- Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-SAG), Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-Heist)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Secaucus, New Jersey